What's in New Mexico Cancer Research Alliance's pipeline?

New Mexico Cancer Research Alliance has 12 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 4 in Phase 2, 5 in Phase 1.

Which companies overlap with New Mexico Cancer Research Alliance's portfolio?

Top competitors by shared drug class: AstraZeneca, Acacia Pharma Ltd, Akeso, Angion Biomedica Corp, AB Science.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/new-mexico-cancer-research-alliance.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

New Mexico Cancer Research Alliance — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

New Mexico Cancer Research Alliance pipeline: 0 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 4 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Gemcitabine and Oxaliplatin	Gemcitabine and Oxaliplatin	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)		Oncology
paclitaxel, docetaxel, taxane	paclitaxel, docetaxel, taxane	phase 3

Therapeutic area mix

Oncology · 3
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
Acacia Pharma Ltd · 1 shared drug class
Akeso · 1 shared drug class
Angion Biomedica Corp · 1 shared drug class
AB Science · 1 shared drug class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for New Mexico Cancer Research Alliance:

Cite this brief

Drug Landscape (2026). New Mexico Cancer Research Alliance — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/new-mexico-cancer-research-alliance. Accessed 2026-05-16.